Bioventus (NASDAQ:BVS) Posts Earnings Results, Hits Estimates

Bioventus (NASDAQ:BVS) issued its quarterly earnings data on Wednesday. The company reported $0.22 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.22, FiscalAI reports. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The business had revenue of $153.21 million for the quarter. Bioventus updated its FY 2026 guidance to 0.750-0.790 EPS.

Here are the key takeaways from Bioventus’ conference call:

• Positive Sentiment: Bioventus reported second-quarter revenue of $153 million, up 4% year over year, with Pain Treatments revenue rising 12% to $82 million, led by double-digit volume growth in DUROLANE.
• Positive Sentiment: The company reaffirmed its 2026 guidance for revenue of $600 million–$610 million, adjusted EPS of $0.75–$0.79, and operating cash flow of $84 million–$89 million, while expecting stronger growth in the second half.
• Positive Sentiment: Management cited encouraging adoption indicators for PRP, PNS, and Ultrasonics, including accelerating capital placements, disposable reorders, trial-to-implant conversions, and new large-account wins. It plans to increase investment in these growth drivers, particularly PNS, in the second half.
• Positive Sentiment: Adjusted EBITDA margin expanded to 23%, adjusted EPS increased to $0.22, and the company repaid $24 million of debt during the quarter. Net leverage fell below 2x, with management targeting below 1.5x by year-end.
• Neutral Sentiment: The board launched a strategic review after receiving multiple expressions of interest and an unsolicited acquisition proposal, with options including a potential sale or continued standalone execution. Management provided no further details on timing or valuation.

Bioventus Trading Down 9.1%

BVS traded down $1.39 during trading on Thursday, hitting $13.87. 456,313 shares of the company’s stock were exchanged, compared to its average volume of 522,104. Bioventus has a 1 year low of $6.26 and a 1 year high of $15.89. The stock has a 50 day moving average price of $10.59 and a 200 day moving average price of $9.61. The firm has a market cap of $1.16 billion, a P/E ratio of 33.91, a price-to-earnings-growth ratio of 1.71 and a beta of 0.63. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08.

Wall Street Analyst Weigh In

BVS has been the subject of several recent analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of Bioventus in a research note on Tuesday, June 16th. Barrington Research set a $18.00 price target on Bioventus in a report on Thursday. Craig Hallum reaffirmed a “buy” rating on shares of Bioventus in a research note on Thursday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Bioventus currently has an average rating of “Buy” and an average price target of $15.75.

Key Headlines Impacting Bioventus

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: The board launched a review after receiving an unsolicited acquisition proposal and multiple other expressions of interest. A potential sale could create a takeover premium for shareholders, although no transaction is assured. Bioventus weighs acquisition offer
• Positive Sentiment: Second-quarter revenue rose 3.8% to $153.2 million, supported by 11.5% growth in Pain Treatments, including strong volume for Durolane. Adjusted EPS increased to $0.22 from $0.21, meeting analyst expectations, while adjusted EBITDA rose 4% to $35.3 million. Bioventus second-quarter financial results
• Positive Sentiment: Bioventus reported $0.47 in GAAP diluted EPS versus $0.11 a year earlier, although the improvement was significantly aided by the release of a $24.6 million deferred-tax valuation allowance. The company also generated $19.9 million in operating cash flow and prepaid $20 million of term debt, reducing future interest costs. Bioventus fiscal second-quarter earnings
• Neutral Sentiment: Management reaffirmed 2026 revenue guidance of $600 million to $610 million, adjusted EPS of $0.75 to $0.79, and operating cash flow of $84 million to $89 million. The outlook is broadly consistent with analyst expectations rather than a fresh upgrade. Bioventus 2026 second-quarter results presentation
• Negative Sentiment: Growth remains concentrated in Pain Treatments: Surgical Solutions revenue declined 4.5% and Restorative Therapies revenue fell 2.4%. The strategic review also carries execution risk, potential transaction costs, and no guarantee that a sale or other deal will be completed. Bioventus strategic alternatives review

Institutional Trading of Bioventus

Several large investors have recently added to or reduced their stakes in BVS. Marshall Wace LLP raised its position in shares of Bioventus by 0.4% in the 4th quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock valued at $2,149,000 after purchasing an additional 1,281 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after purchasing an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in Bioventus by 16.2% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock valued at $101,000 after buying an additional 1,887 shares during the last quarter. Deutsche Bank AG raised its stake in Bioventus by 8.2% during the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock valued at $187,000 after buying an additional 1,908 shares in the last quarter. Finally, Engineers Gate Manager LP raised its position in shares of Bioventus by 6.0% during the 4th quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock valued at $513,000 after acquiring an additional 3,909 shares in the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.